Genmab and Abbvie file for cancer drug approval in Japan
After having filed epcoritamab review for by the EMA and the FDA earlier this year, Genmab and Abbvie submit an application with the Japanese health authority.
by marketwire, translated by helene von tabouillot
According to a press release, Genmab and partner Abbvie have just submitted a market authorization application for cancer drug epcoritamab in Japan in the indication for diffuse large B cell lymphoma (LBCL) patients who have already undergone two treatments but experienced recurrences.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Ferring gets cancer nod from FDA
For subscribers
Genmab presents promising new data for cancer hope in US
For subscribers
